Literature DB >> 10997858

Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.

K Ogawa1, T Yamada, Y Tsujioka, J Taguchi, M Takahashi, Y Tsuboi, Y Fujino, M Nakajima, T Yamamoto, H Akatsu, S Mitsui, N Yamaguchi.   

Abstract

Neurosin, a novel type of trypsin-like serine protease, has been shown to be preferentially expressed in human brain by northern blotting. We examined neurosin immunolabeling in the brains of neurologically normal persons and patients with Alzheimer's disease (AD) and with Parkinson's disease. We also identified the expression of the mRNA for neurosin by in situ hybridization histochemistry and reverse transcription-polymerase chain reaction (RT-PCR). The neurosin antibody stained all of the nuclei of various cell types. In neurons, there was also staining of neuronal cytoplasm, nucleoli and their processes. In AD, staining of neurons with processes was rare in the damaged areas. Some senile plaques, extracellular tangles and Lewy bodies were also positive for neurosin. Expression of the mRNA for neurosin was seen in neurons in the gray matter, and in microglial cells in the white matter. In AD, the intensity of the signal for neurosin mRNA in the gray matter was decreased compared with normal control brains. The relative levels of neurosin mRNA in AD brains, measured by RT-PCR, were lower than those in controls. These results suggest that in human brain neurosin plays various physiological roles, and that in AD this molecule, like other serine proteases, may have a role in the degradation of such substances as beta-amyloid protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997858     DOI: 10.1046/j.1440-1819.2000.00731.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  29 in total

1.  A genome-wide study reveals rare CNVs exclusive to extreme phenotypes of Alzheimer disease.

Authors:  Anne Rovelet-Lecrux; Solenn Legallic; David Wallon; Jean-Michel Flaman; Olivier Martinaud; Stéphanie Bombois; Adeline Rollin-Sillaire; Agnès Michon; Isabelle Le Ber; Jérémie Pariente; Michèle Puel; Claire Paquet; Bernard Croisile; Catherine Thomas-Antérion; Martine Vercelletto; Richard Lévy; Thierry Frébourg; Didier Hannequin; Dominique Campion
Journal:  Eur J Hum Genet       Date:  2011-12-14       Impact factor: 4.246

2.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

Review 3.  Kallikreins - The melting pot of activity and function.

Authors:  Magdalena Kalinska; Ulf Meyer-Hoffert; Tomasz Kantyka; Jan Potempa
Journal:  Biochimie       Date:  2015-09-25       Impact factor: 4.079

Review 4.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 5.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

6.  Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration.

Authors:  Maja Radulovic; Hyesook Yoon; Nadya Larson; Jianmin Wu; Rachel Linbo; Joshua E Burda; Eleftherios P Diamandis; Sachiko I Blaber; Michael Blaber; Michael G Fehlings; Isobel A Scarisbrick
Journal:  J Neuropathol Exp Neurol       Date:  2013-11       Impact factor: 3.685

Review 7.  Unleashing the therapeutic potential of human kallikrein-related serine proteases.

Authors:  Ioannis Prassas; Azza Eissa; Gennadiy Poda; Eleftherios P Diamandis
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

Review 8.  Cell Biology and Pathophysiology of α-Synuclein.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

9.  Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.

Authors:  Meike Diepenbroek; Nicolas Casadei; Hakan Esmer; Takaomi C Saido; Jiro Takano; Philipp J Kahle; Ralph A Nixon; Mala V Rao; Ronald Melki; Laura Pieri; Stefan Helling; Katrin Marcus; Rejko Krueger; Eliezer Masliah; Olaf Riess; Silke Nuber
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

Review 10.  Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease.

Authors:  Sang Myun Park; Kwang Soo Kim
Journal:  Prion       Date:  2012-11-15       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.